SMMT - Summit Therapeutics Inc

24.11
0.645   2.675%

Share volume: 13,089,170
Last Updated: 04-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$23.46
0.64
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
46%
Profitability 35%
Dept financing 28%
Liquidity 50%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-34.31%
1 Month
24.99%
3 Months
31.75%
6 Months
31.75%
1 Year
31.75%
2 Year
31.75%
Key data
Stock price
$24.11
P/E Ratio 
0.00
DAY RANGE
$23.04 - $26.97
EPS 
-$0.08
52 WEEK RANGE
$15.55 - $36.91
52 WEEK CHANGE
$31.75
MARKET CAP 
13.160 B
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-30-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$10,868,942
AVERAGE 30 VOLUME 
$6,496,836
Company detail
CEO: Robert W. Duggan
Region: US
Website: summittxinc.com
Employees: 110
IPO year: 2015
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Summit Therapeutics Inc. conducts clinical programs focusing on Clostridioides difficile infection (CDI) The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Recent news
loading